摘要
Abstract
Objective:To investigate the clinical efficacy of secuchiumab in the treatment of ankylosing spondylitis and its effect on spinal function.Method:80 patients with ankylosing spondylitis(AS)admitted to Jinjiang City Hospital from January 2022 to January 2024 were selected as the study objects.They were divided into Adamu group and Secuchiu group according to different medication regimens,with 40 cases in each group.Adamu group received adamumab treatment,while the Secuchiumab group received secuchiumab treatment,and all patients continued to receive treatment for 3 months.The treatment effectiveness of the two groups was compared.Spinal function(ankylosing spondylitis Function Index(BASFI),Bath Ankylosing Spondylitis Metrology index(BASMI),morning stiffness duration],laboratory indicators[erythrocyte subsidence rate(ESR),C-reactive protein(CRP)]and drug safety were compared between the two groups before and after treatment.Result:The effective rate of Sikuchiyou group was higher than that of Adamu group,and the difference was statistically significant(P<0.05).After treatment,the BASFI and BASMI of Secuchiyou group were lower than those of Adamu group,the duration of morning stiffness was shorter than that of Adamu group(P<0.05).After treatment,compared with Adamu group,both ESR and CRP in Secuchiu group were lower(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The treatment effect of secuchiumab in patients with AS is better than that of adalimumab,which is beneficial to improve the spinal function of patients,shorten the morning rigor time,promote blood circulation,reduce inflammatory factors,and no obvious adverse reactions were observed.关键词
司库奇尤单抗治疗/强直性脊柱炎/临床疗效/脊柱功能/炎性因子/不良反应Key words
Secuchiumab therapy/Ankylosing spondylitis/Clinical effect/Spinal function/Inflammatory factors/Adverse reaction
